Access to medicines for treating people with cryptococcal meningitis

Cryptococcal meningitis accounts for one in five AIDS-related deaths globally. WHO guidelines strongly recommend a single high-dose of liposomal amphotericin B as part of preferred treatment, but this drug remains unaffordable in most low- and middle-income countries. A proactive approach is needed...

Descripción completa

Detalles Bibliográficos
Autores principales: Burry, Jessica, Casas, Carmen Perez, Ford, Nathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614173/
https://www.ncbi.nlm.nih.gov/pubmed/36037037
http://dx.doi.org/10.1093/cid/ciac689/6678599
Descripción
Sumario:Cryptococcal meningitis accounts for one in five AIDS-related deaths globally. WHO guidelines strongly recommend a single high-dose of liposomal amphotericin B as part of preferred treatment, but this drug remains unaffordable in most low- and middle-income countries. A proactive approach is needed from manufacturers and other stakeholders to improve access.

Ejemplares similares